Comparing newborn outcomes after prenatal exposure to individual antidepressants: A retrospective cohort study

被引:11
|
作者
Marks, Claire [1 ]
Silvola, Rebecca [2 ]
Teal, Evgennia [3 ]
Quinney, Sara K. [1 ,2 ]
Haas, David M. [1 ,2 ]
机构
[1] Indiana Univ Sch Med, Dept Obstet & Gynecol, 550 N Univ Blvd,UH 2440, Indianapolis, IN 46033 USA
[2] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN USA
[3] Regenstrief Inst Hlth Care, Indianapolis, IN USA
来源
PHARMACOTHERAPY | 2021年 / 41卷 / 11期
基金
美国国家卫生研究院;
关键词
abstinence syndrome; antidepressants; exposure; newborn outcomes; pregnancy; DEPRESSION; PREGNANCY; RECEPTOR;
D O I
10.1002/phar.2628
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective To compare associations between individual antidepressants and newborn outcomes. Design Retrospective cohort study. Setting Deliveries in a large, US medical system. Population Women who received at least one antidepressant prescription 3 months prior to conception through delivery. Methods Eligible women had maternal characteristics and newborn outcomes extracted from medical record data. Exposure was defined by the timing of the prescription during pregnancy. Main outcome measures Newborn outcomes (any adaptation syndrome, neonatal intensive care unit (NICU) admission) were analyzed for each antidepressant and compared using standard statistics and multivariable regression compared to exposure to bupropion. Odds of outcomes based on timing of exposure were also explored. Results A total of 3,694 women were analyzed. Rates of any adaptation syndrome (p < 0.001), NICU admission (p < 0.001), and transient tachypnea of newborn (TTN) (p = 0.006) were significantly different between drugs. Infants exposed to duloxetine had the highest rates of NICU admissions (39.6%) and adaptation syndromes (15.1%). Venlafaxine-exposed infants had the highest rates of TTN (18.2%). Controlling for maternal age, race, insurance, and gestational age at delivery, early pregnancy antidepressant exposure was associated with adaptation syndrome and NICU admission for both duloxetine (adjusted odds ratio (aOR) 2.31 [95% Confidence Interval (CI) 1.11-4.80] and aOR 2.47 [95% CI 1.40-4.34], respectively) and escitalopram (aOR 1.72 [95% CI 1.09-2.70] and aOR 1.64 [95% CI 1.21-2.22], respectively). Exposure in the third trimester was associated with any adaptation syndrome for citalopram, duloxetine, escitalopram, fluoxetine, sertraline, and venlafaxine and NICU admission for bupropion, citalopram, duloxetine, escitalopram, and fluoxetine. Conclusion Duloxetine and escitalopram appear to have the strongest associations with any adaptation syndrome and NICU admission whereas bupropion and sertraline tended to have among the lowest risks of these outcomes. These results can help providers and patients discuss choice of individual antidepressant drugs during pregnancy.
引用
收藏
页码:907 / 914
页数:8
相关论文
共 50 条
  • [1] Pregnancy outcomes after prenatal exposure to antidepressants
    Borgida, Adam F.
    Feldman, Deborah M.
    Ricci, Stephanie
    Ingardia, Charles J.
    OBSTETRICS AND GYNECOLOGY, 2006, 107 (04): : 60S - 61S
  • [2] Prenatal marijuana exposure and neonatal outcomes: a retrospective cohort study
    Jones, Michael James
    Lotfi, Asma
    Lin, Amber
    Gievers, Ladawna L.
    Hendrickson, Robert
    Sheridan, David C.
    BMJ OPEN, 2022, 12 (09):
  • [3] Risk of Pregnancy Loss after Prenatal Exposure to Doxycycline: A Retrospective Cohort Study
    Chen, Hung-Kai
    Thuy Thai
    Smolinski, Nicole E.
    Wang, Yanning
    Ewig, Celeste L. Y.
    Muschett, Matthew
    Kulkarni, Priyanka
    Wen, Wen
    Gilboa, Suzanne
    Meaney-Delman, Dana
    Rasmussen, Sonja A.
    Winterstein, Almut
    BIRTH DEFECTS RESEARCH, 2024, 116 : S51 - S51
  • [4] Risk of Pregnancy Loss after Prenatal Exposure to Doxycycline: A Retrospective Cohort Study
    Chen, Hung-Kai
    Thai, Thuy N.
    Smolinski, Nicole E. E.
    Wang, Yanning
    Ewig, Celeste L. Y.
    Muschett, Matthew R.
    Kulkarni, Priyanka J.
    Wen, Wen
    Gilboa, Suzanne
    Delman, Dana Meaney
    Rasmussen, Sonja A.
    Winterstein, Almut G.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 1 - 2
  • [5] Birth outcomes following prenatal exposure to antidepressants
    Pearson, Kimberly H.
    Nonacs, Ruta M.
    Vigueya, Adele C.
    Heller, Vicki L.
    Petrillo, Laura F.
    Brandes, Mina
    Hennen, John
    Cohen, Lee S.
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (08) : 1284 - 1289
  • [6] Challenges in Determining Outcomes of Prenatal Exposure to Antidepressants
    Nonacs, Ruta M.
    Cohen, Lee S.
    JOURNAL OF CLINICAL PSYCHIATRY, 2020, 81 (03)
  • [7] Association Between Prenatal Opioid Exposure and Neurodevelopmental Outcomes in Early Childhood: A Retrospective Cohort Study
    Xuerong Wen
    Oluwadolapo D. Lawal
    Nicholas Belviso
    Kelly L. Matson
    Shuang Wang
    Brian J. Quilliam
    Kimford J. Meador
    Drug Safety, 2021, 44 : 863 - 875
  • [8] Association Between Prenatal Opioid Exposure and Neurodevelopmental Outcomes in Early Childhood: A Retrospective Cohort Study
    Wen, Xuerong
    Lawal, Oluwadolapo D.
    Belviso, Nicholas
    Matson, Kelly L.
    Wang, Shuang
    Quilliam, Brian J.
    Meador, Kimford J.
    DRUG SAFETY, 2021, 44 (08) : 863 - 875
  • [9] Pregnancy outcomes after prenatal exposure to echinacea: the Norwegian Mother and Child Cohort Study
    K. Heitmann
    G. C. Havnen
    L. Holst
    H. Nordeng
    European Journal of Clinical Pharmacology, 2016, 72 : 623 - 630
  • [10] Pregnancy outcomes after prenatal exposure to echinacea: the Norwegian Mother and Child Cohort Study
    Heitmann, K.
    Havnen, G. C.
    Holst, L.
    Nordeng, H.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (05) : 623 - 630